200 related articles for article (PubMed ID: 7471373)
1. Torsades de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities.
Horowitz LN; Greenspan AM; Spielman SR; Josephson ME
Circulation; 1981 May; 63(5):1120-8. PubMed ID: 7471373
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced torsade de pointes.
Raehl CL; Patel AK; LeRoy M
Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
4. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
[TBL] [Abstract][Full Text] [Related]
5. Torsades de pointes, a common arrhythmia, induced by medication.
Ko PT; Gulamhusein S; Kostuk WJ; Klein GJ
Can Med Assoc J; 1982 Sep; 127(5):368-72. PubMed ID: 7104914
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
7. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
[TBL] [Abstract][Full Text] [Related]
8. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
[TBL] [Abstract][Full Text] [Related]
9. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
Singh BN; Kehoe R; Woosley RL; Scheinman M; Quart B
Am Heart J; 1995 Jan; 129(1):87-97. PubMed ID: 7817931
[TBL] [Abstract][Full Text] [Related]
10. "Les torsades de pointes": an unusual ventricular arrhythmia.
Smith WM; Gallagher JJ
Ann Intern Med; 1980 Oct; 93(4):578-84. PubMed ID: 7001975
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents.
Belhassen B; Shapira I; Shoshani D; Paredes A; Miller H; Laniado S
Circulation; 1987 Apr; 75(4):809-16. PubMed ID: 3829343
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy.
Markel ML; Miles WM; Luck JC; Klein LS; Prystowsky EN
Circulation; 1993 Mar; 87(3):783-92. PubMed ID: 8443899
[TBL] [Abstract][Full Text] [Related]
13. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
14. The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications.
Waxman HL; Buxton AE; Sadowski LM; Josephson ME
Circulation; 1983 Jan; 67(1):30-7. PubMed ID: 6847803
[TBL] [Abstract][Full Text] [Related]
15. Torsades de pointes induced by transesophageal atrial stimulation after administration of almokalant.
Darpö B; Allared M; Edvardsson N
Int J Cardiol; 1996 Mar; 53(3):311-3. PubMed ID: 8793587
[TBL] [Abstract][Full Text] [Related]
16. Limitations of failure of procainamide during electrophysiologic testing to predict response to other medical therapy.
Rae AP; Sokoloff NM; Webb CR; Spielman SR; Greenspan AM; Horowitz LN
J Am Coll Cardiol; 1985 Aug; 6(2):410-6. PubMed ID: 4019928
[TBL] [Abstract][Full Text] [Related]
17. Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia?
Krishnan SC; Galvin J; McGovern B; Garan H; Ruskin JN
J Cardiovasc Electrophysiol; 1997 Sep; 8(9):1055-61. PubMed ID: 9300303
[TBL] [Abstract][Full Text] [Related]
18. [Torsades de pointes initiated by slow ventricular stimulation].
Fontaine G; Frank R; Lascault G; Tonet JL; Fillette F; Grosgogeat Y
Arch Mal Coeur Vaiss; 1983 Aug; 76(8):918-24. PubMed ID: 6414425
[TBL] [Abstract][Full Text] [Related]
19. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
[TBL] [Abstract][Full Text] [Related]
20. Detailed analysis of 24 hour ambulatory electrocardiographic recordings during ventricular fibrillation or torsade de pointes.
Lewis BH; Antman EM; Graboys TB
J Am Coll Cardiol; 1983 Sep; 2(3):426-36. PubMed ID: 6192159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
